HAMILTON — Colgate Men's Lacrosse is once again joining lacrosse teams and players across the country in accepting the Pediatric Cancer Research Foundation's LaCROSSe Out Cancer Challenge. The players are using their time and talent to raise visibility about the critical need for increasing support for pediatric cancer research.
 
By accepting the challenge, the team completed 47 days of wall ball this past fall and is in the process of completing 47 days this spring leading up to its LaCROSSe Out Cancer game against Army Saturday at 2 p.m. inside Andy Kerr Stadium.
 
Each day, 47 American children are diagnosed with cancer, and more children under 20 years old are lost to cancer annually than any other disease.
 
Colgate head coach Matt Karweck looks forward to continuing to raise awareness about this important cause.
 
"We are super excited to partner with LaCROSSe out Cancer again and bring awareness to the 47 kids diagnosed with cancer every day in the United States. It is something near and dear to our program." Karweck said. 

"This is an incredible opportunity for our program or any program to recognize this cause. We look forward to continuing the battle as we go together," he added. 
 
Colgate accepted the challenge for the second straight year in support of junior midfielder Hunter Drouin, who was diagnosed with Wilms Tumor as a toddler. Because of advancements in research, Hunter has been in remission for the past 17 years.

"LaCROSSe Out Cancer is more than just a fundraiser. It is about inspiration, creating change, and telling kids they can do it. Cancer is not the end of the road. When you get through it, you can live life and achieve great things," Drouin said. 

Due to research advances, overall survival rates have grown by 70 percent in the past 40 years. Still, about 20 percent of kids with pediatric cancer do not survive today, and two-thirds of those who do will suffer long-lasting chronic health conditions from their treatment. To address these challenges, the Pediatric Cancer Research Foundation invests in research specifically for children's and adolescents' developing bodies.
 
The Pediatric Cancer Research Foundation is proud to have been an integral part in funding the research that created the protocol that today is used worldwide to treat Wilms Tumor.
 
For more information, please click HERE.